Trials / Completed
CompletedNCT01834950
Identification of Early Markers of Response and Resistance to Trastuzumab
Identification of Early Markers of Response and Resistance to Trastuzumab in Patients With Localized Human Epidermal Growth Factor Receptor-2(HER-2)-Positive Breast Cancer Candidates for Breast Conserving Surgery
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab. It is a prognostic factor study recruiting all consecutive cases of HER-2 positive breast cancer eligible for a pre-operative treatment by trastuzumab, followed by breast conserving surgery. The investigators will study the association between the value of biomarkers measured at diagnosis and the Response Evaluation Criteria in Solid Tumors response (partial and complete response) using a logistic regression (main analysis).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood test |
Timeline
- Start date
- 2013-03-27
- Primary completion
- 2017-12-10
- Completion
- 2017-12-10
- First posted
- 2013-04-18
- Last updated
- 2018-03-29
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01834950. Inclusion in this directory is not an endorsement.